Sublingual Immunotherapy
Publication Date: March 1, 2017
Key Points
Key Points
- It is crucial that the practicing allergist separate the data on FDA reviewed products that have led to approval of these products (ie, dust mites, grass and ragweed tablets) from the data in the literature with other allergens and other formulations (eg, liquid formulations) that have not undergone the rigor of FDA review.
Diagnosis
...agnosis...
...able 1. World Allergy Organization Grading S...
...iption of Local Adverse Effects Related to SLI...
Treatment
Treatme...
...only FDA-approved SLIT products for the...
...n should be aware that SLIT may not be suitab...
...se FDA-approved SLIT products very cautiously in...
...me dosing equivalence between SLIT tablets and ext...
...nister the patient’s first dose of SLIT in a me...
...phrine (either an autoinjector or other form...
...’s SLIT dose if they have missed treatment f...
...nts receiving SLIT therapy for regular follow-...
...products for SLIT in the United State...
...e 3. Suggested Guidelines for the Practicin...
...ble 4. FDA-Approved Sublingual TabletsHaving trou...